No Data
No Data
Tianfeng: Maintains a 'buy' rating on Yue Yuen Ind, stating that it may benefit from Adidas' guidance adjustment.
Tianfeng research reports released, maintaining profit forecasts for Yue Yuen Ind (00551), expecting company FY24-26 revenues to be 8.65 billion USD, 9.645 billion USD, 10.935 billion USD; net profit attributable to owners respectively 0.38 billion USD, 0.42 billion USD, 0.46 billion USD; EPS respectively 0.24 USD/share, 0.26 USD/share, 0.29 USD/share; corresponding PEs respectively 8X, 7X, 6X, maintaining a 'buy' rating. The company collaborates with Nike, adidas, Asics, NewBalance, Salomon and
tianfeng (601162.SH): There is no plan for merger and reorganization or other significant matters that should be disclosed but have not been disclosed.
Gelonghui October 16th | tianfeng Securities (601162.SH) stated on the interactive platform that the company does not have any merger and reorganization plans or other significant undisclosed matters that should be disclosed.
tianfeng Securities: Maintains a "buy" rating on 361 degrees, with online growth leading in Q3 24.
Tianfeng Securities released a research report stating that it maintains a 'buy' rating on 361 degrees (01361), expecting the company's revenue in 2024 and 2025 to be 10.09 billion RMB, 11.69 billion RMB, and 13.45 billion RMB respectively; net profit attributable to shareholders to be 1.11 billion RMB, 1.29 billion RMB, and 1.53 billion RMB respectively; corresponding EPS to be 0.54 RMB/share, 0.62 RMB/share, and 0.74 RMB/share. Tianfeng Securities' main points are as follows: In Q3 2024, 361 degrees' offline main brand retail performance was good, with a year-on-year growth of about 10%.
Tianfeng: Maintaining a "buy" rating on chow tai fook. Continued rise in gold prices may temporarily hinder consumer enthusiasm.
Tianfeng Securities released research reports stating that they maintain a "buy" rating on Chow Tai Fook (01929), as the strong performance of gold prices affects gold jewelry consumption. At the same time, the optimization of gross margin with the increase in the proportion of fixed-price products, adjusting the company's profit forecast. It is expected that the revenue for FY25-27 will be 94.5 billion Hong Kong dollars, 103.9 billion Hong Kong dollars, and 114.5 billion Hong Kong dollars respectively (previously 113.6 billion Hong Kong dollars, 121.4 billion Hong Kong dollars, 130.3 billion Hong Kong dollars), and the net profit attributable to owners will be 5.98 billion Hong Kong dollars, 6.91 billion Hong Kong dollars, 7.94 billion Hong Kong dollars (previously 6.9 billion Hong Kong dollars, 7.6 billion Hong Kong dollars, 8.5 billion Hong Kong dollars); EPS will be 0.60 Hong Kong dollars.
Tianfeng Securities: Innovent Bio's 2024 interim report meets expectations, maintaining a "buy" rating.
Tianfeng Securities released a research report stating that they maintain a 'buy' rating for Innovent Bio (01801), considering the continuous increase in sales volume of the company's listed products, and multiple R&D pipelines are expected to enter the product harvest period. The revenue expectations for 2024 and 2025 have been raised from 7.225 billion yuan and 9.193 billion yuan to 7.97 billion yuan and 10.235 billion yuan respectively. It is estimated that the revenue in 2026 will reach 13.143 billion yuan. At the same time, the company's net income for 2024 and 2025 has been adjusted from -0.766 billion yuan and -0.17 billion yuan to -0.756 billion yuan and 0.089 billion yuan, with an estimated net income of 10.0 billion yuan in 2026.
The selected announcement from Gelunhui: Will Semiconductor: Net income in the first three quarters is expected to increase by 515.35% to 569.64% year-on-year; Tianfeng Securities: The company does not have any plans for merger and reorganization.
【Performance Data】Dongpeng Beverage (605499.SH): The net income is expected to increase by 57.04% to 64.89% year-on-year in the first three quarters. special treat Tianbang (002124.SZ): It is expected to make a profit of 1.301 billion yuan to 1.351 billion yuan in the first three quarters, turning losses compared to the same period last year. pacific shuanglin bio-pharmacy (000403.SZ): It is expected that the net income in the first three quarters will increase by 60% to 70% year-on-year. Shengnuo Biotechnology (688117.SH): It is expected that the net income in the first three quarters will increase by 43.9% to 75.88% year-on-year. Muyuan Foods (002714.SZ): It is expected to make a profit of 10 billion yuan to 11 billion yuan in the first three quarters.
No Data
No Data